Noh Jung-Hoon, Lee Min Ho, Kim Won Seog, Lim Do Hoon, Kim Sung Tae, Kong Doo-Sik, Nam Do-Hyun, Lee Jung-Il, Seol Ho Jun
Department of Neurosurgery, Samsung Medical Centre, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Korea.
Acta Neurochir (Wien). 2015 Apr;157(4):569-76. doi: 10.1007/s00701-015-2344-5. Epub 2015 Feb 8.
Glioblastoma (GBM) is the most common and malignant brain tumor in adults. Despite therapeutic advances, almost all patients eventually experience tumor recurrence. Leptomeningeal spread (LMS) is not a rare condition of recurrence. However, the standard management protocol of LMS has not been established. The aim of this study is to report the risk of (LMS) and the prognosis between treatment modalities in GBM patients.
A retrospective review was conducted of 321 patients who were diagnosed with GBM between January 2006 and December 2010. In 75 patients, LMS of tumor was detected by magnetic resonance image and/or cerebrospinal fluid cytology. Twelve patients underwent intrathecal methotrexate (IT-MTX) chemotherapy. Twenty-two patients underwent other salvage treatments. Forty-one patients underwent conservative management. We analyzed the possible clinical factors for LMS. Further, we examined overall survival and survival after diagnosis of LMS for several treatment modalities.
In patients without LMS, median overall survival was 479 days, whereas that in patients with LMS it was 401 days. Younger age and larger initial tumor size were related to more frequent LMS incidence. Proximity between tumor margin and ventricle did not affect LMS. However, median duration from initial diagnosis to LMS was significantly different according to the distance to the ventricle. IT-MTX group's overall survival was 583 days, which is statistically no longer than that of the other treatment group and the conservative management group. However, an additional survival benefit may exist compared to the conservative treatment. The median survival of the IT-MTX group was 181 days compared with 91 days for the conservative management group.
Treatment of LMS is mainly palliative. IT-MTX is generally the first-line treatment modality of LMS. Prediction and prevention of LMS is crucial because its treatment has been limited. Further approaches to improve the therapeutic effect should be established.
胶质母细胞瘤(GBM)是成人中最常见且恶性程度最高的脑肿瘤。尽管治疗取得了进展,但几乎所有患者最终都会出现肿瘤复发。软脑膜播散(LMS)是一种并不罕见的复发情况。然而,LMS的标准管理方案尚未确立。本研究的目的是报告GBM患者中LMS的风险以及不同治疗方式之间的预后情况。
对2006年1月至2010年12月期间诊断为GBM的321例患者进行回顾性研究。在75例患者中,通过磁共振成像和/或脑脊液细胞学检查发现肿瘤的LMS。12例患者接受了鞘内甲氨蝶呤(IT-MTX)化疗。22例患者接受了其他挽救性治疗。41例患者接受了保守治疗。我们分析了LMS可能的临床因素。此外,我们还研究了几种治疗方式的总生存期以及LMS诊断后的生存期。
在无LMS的患者中,中位总生存期为479天,而有LMS的患者为401天。年龄较小和初始肿瘤体积较大与LMS发生率较高有关。肿瘤边缘与脑室的距离并不影响LMS。然而,根据与脑室的距离,从初始诊断到LMS的中位持续时间存在显著差异。IT-MTX组的总生存期为583天,在统计学上不比其他治疗组和保守治疗组更长。然而,与保守治疗相比可能存在额外的生存获益。IT-MTX组的中位生存期为181天,而保守治疗组为91天。
LMS的治疗主要是姑息性的。IT-MTX通常是LMS的一线治疗方式。LMS的预测和预防至关重要,因为其治疗方法有限。应建立进一步提高治疗效果的方法。